Spring Valley Acquisition Corporation II (SVII) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SVII • KYG837521080

12.7 USD
-1.15 (-8.3%)
At close: Oct 20, 2025
12.7 USD
0 (0%)
After Hours: 10/20/2025, 8:17:46 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

SVII gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. SVII scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SVII has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year SVII was profitable.
  • SVII had a negative operating cash flow in the past year.
SVII Yearly Net Income VS EBIT VS OCF VS FCFSVII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 2M 4M 6M 8M 10M

1.2 Ratios

Industry RankSector Rank
ROA 9.12%
ROE 9.99%
ROIC N/A
ROA(3y)10.36%
ROA(5y)N/A
ROE(3y)11.02%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SVII Yearly ROA, ROE, ROICSVII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 10 20

1.3 Margins

  • SVII does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SVII Yearly Profit, Operating, Gross MarginsSVII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • SVII has less shares outstanding than it did 1 year ago.
  • There is no outstanding debt for SVII. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SVII Yearly Shares OutstandingSVII Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
SVII Yearly Total Debt VS Total AssetsSVII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • SVII has an Altman-Z score of 32.80. This indicates that SVII is financially healthy and has little risk of bankruptcy at the moment.
  • SVII has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 32.8
ROIC/WACCN/A
WACCN/A
SVII Yearly LT Debt VS Equity VS FCFSVII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 0.13 indicates that SVII may have some problems paying its short term obligations.
  • A Quick Ratio of 0.13 indicates that SVII may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
SVII Yearly Current Assets VS Current LiabilitesSVII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 500K 1M 1.5M 2M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • SVII shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -86.85%.
EPS 1Y (TTM)-86.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-113.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • SVII is valuated quite expensively with a Price/Earnings ratio of 181.43.
  • SVII is valuated expensively when we compare the Price/Earnings ratio to 28.23, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 181.43
Fwd PE N/A
SVII Price Earnings VS Forward Price EarningsSVII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SVII Per share dataSVII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SVII does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

Spring Valley Acquisition Corporation II

NASDAQ:SVII (10/20/2025, 8:17:46 PM)

After market: 12.7 0 (0%)

12.7

-1.15 (-8.3%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)08-13
Earnings (Next)11-12
Inst Owners34.21%
Inst Owner Change-9.99%
Ins Owners1.21%
Ins Owner Change0%
Market Cap125.48M
Revenue(TTM)N/A
Net Income(TTM)2.40M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 181.43
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.22
P/tB 5.22
EV/EBITDA N/A
EPS(TTM)0.07
EY0.55%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0
BVpS2.43
TBVpS2.43
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.96
Profitability
Industry RankSector Rank
ROA 9.12%
ROE 9.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)10.36%
ROA(5y)N/A
ROE(3y)11.02%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z 32.8
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-86.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-113.97%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.38%
OCF growth 3YN/A
OCF growth 5YN/A

Spring Valley Acquisition Corporation II / SVII FAQ

Can you provide the ChartMill fundamental rating for Spring Valley Acquisition Corporation II?

ChartMill assigns a fundamental rating of 1 / 10 to SVII.


Can you provide the valuation status for Spring Valley Acquisition Corporation II?

ChartMill assigns a valuation rating of 0 / 10 to Spring Valley Acquisition Corporation II (SVII). This can be considered as Overvalued.


What is the profitability of SVII stock?

Spring Valley Acquisition Corporation II (SVII) has a profitability rating of 0 / 10.


What is the financial health of Spring Valley Acquisition Corporation II (SVII) stock?

The financial health rating of Spring Valley Acquisition Corporation II (SVII) is 5 / 10.